- CEO
- Yoshinori Hirai
- Full Time Employees
- 52,896
- Sector
- Consumer durables
- Industry
- Home furnishings
- Address
- 1-5-1, Marunouchi Tokyo TY Japan 100-8405
- IPO Date
- Jun 12, 1950
- Business
- AGC Inc. manufactures and sells glass, electronic materials, chemicals, life science products, ceramics, and related offerings worldwide. The Tokyo-based company, founded in 1907 and formerly known as Asahi Glass Co., Ltd. until its rebranding in 2018, operates through segments including architectural glass; automotive glass such as laminated, tempered, sound insulation, low-emissivity, light control, and cover glass for in-vehicle displays along with glass antennas; display glass substrates for TFT-LCD and OLED; electronic materials encompassing synthetic fused silica glass, EUV lithography photomask blanks, high-purity silicon carbide jigs, CMP slurry, optoelectronic materials like IR-absorbing filters, and high-performance materials for semiconductors, 5G, and ADAS; essential chemicals including caustic soda, PVC resins, epichlorohydrin, sodium bicarbonate, polyols, and modified silicones; performance chemicals such as fluoropolymers (Fluon ETFE resins and films), fluororubbers, fluorine-based gases, solvents, water and oil repellents, and ion-exchange membranes for chlor-alkali electrolysis; life science CDMO services for biopharmaceuticals (ex vivo gene therapy, single-use bioreactors up to 20,000L), synthetic drugs, and agrochemicals; and ceramics like refractory materials, molding materials, furnace walls, beads, and structural fine ceramics. With production bases in Japan, China, the United States, Europe, Southeast Asia, and other regions, AGC serves automotive, electronics, construction, energy, mobility, and healthcare sectors, holding leading market positions in automotive glass (No. 2 worldwide), car-mounted cover glass (No. 2 worldwide), EUV photomask blanks (No. 1 worldwide), biopharma CDMO for ex vivo gene therapy (No. 1 worldwide), fluorinated resins like Fluon ETFE (No. 1 worldwide), and caustic soda/PVC in Southeast Asia (No. 1). Recent developments encompass the 2023 establishment of a dedicated Life Science Company with new reportable segments; a September 2024 strategic partnership with MEDINET for cell therapy CDMO, including human resource exchanges and planned 2025-2026 launches at AGC Biologics' Yokohama site; ongoing plant expansions in Thailand to boost chlor-alkali capacity; the medium-term AGC plus-2026 plan emphasizing ambidextrous management of core and strategic businesses (electronics, life science, mobility), sustainability KPIs for GHG reductions and product indices, value creation DX with generative AI and digital twins, business restructuring for low-ROCE areas like biopharma CDMO and automotive Europe, pricing revisions, and ROE targets exceeding 5% by 2026; and 2023 investments of 100 billion JPY in production efficiency alongside prior acquisitions like Corning's Display Technologies business in 2021.